Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > New Investor Presentation (June 2021)

<< Previous

Bullboard Posts

Next >>

Post by IrishCanuckon Jun 04, 2021 11:44am

252 Views

Post# 33329938

New Investor Presentation (June 2021)

Not much different from April, but:

1) It looks like they added on Slide 7 that they're focussing on US, UK and EU4 (Germany, France, Italy and Spain)

2) I don't remember Slide 5 where they highlight two competitor drugs being withdrawn

3) Slide 33 recent and upcoming milestones were updated

Maybe some of these were there before but I don't recall

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages